694 EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma

Leahy, M.; Blay, Jean Yves; Verweij, Jaco J.; Cesne, Axel Le; Duffaud, F.; Hogendoorn, P.C.W.; Balincourt, Christine de; Evrard, V.; Judson, Ian

doi:10.1016/s1359-6349(03)90725-7

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary data from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial with brostallicin, another new minor groove binder, revealed two partial responses and 17 patients with disease stabilization at the end of cycle two among 42 enrolled patients [33].…”

Section: Minor Groove Bindersmentioning

confidence: 99%

RETRACTED ARTICLE: New drug developments for patients with metastatic soft tissue sarcoma

Hartmann

Patel

2005

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

Section: Minor Groove Bindersmentioning

confidence: 99%

RETRACTED ARTICLE: New drug developments for patients with metastatic soft tissue sarcoma

Hartmann

Patel

2005

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Preliminary data of a EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial with brostallicin, another new minor groove binder, revealed two partial responses and in addition 17 patients with disease stabilization at the end of cycle two among 42 included patients [61]. …”

Section: Minor Groove Bindersmentioning

confidence: 99%

Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines

Hartmann

2007

Anti-Cancer Drugs

View full text Add to dashboard Cite

For the subgroup of patients with inoperable gastrointestinal stromal tumors, progress has been made by the rapid development and approval of the targeted therapy imatinib mesylate. Small round cell sarcoma, such as Ewing/PNET, desmoplastic small round cell sarcoma and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensitive and neoadjuvant protocols regardless of size or overt metastatic disease. A limited number of effective agents available for the treatment of patients with metastatic adult soft-tissue sarcoma exists, which have failed anthracyline and ifosfamide-based chemotherapy. Most other high-grade (grading >I) so-called adult-type soft-tissue sarcomas such as fibro, lipo, pleomorphic and synovial sarcoma are treated with a anthracycline-based regimen with or without ifosfamide as front-line therapy. In this review, the therapeutic activities of drugs currently available as second-line treatment in patients with metastatic soft tissue sarcoma are summarized, providing an overview of contentious or emerging treatment issues. In relapsed 'adult-type' soft-tissue sarcomas trofosfamide, gemcitabine and ecteinascidin (ET-743) appear to be drugs associated with moderate activity and an acceptable toxicity profile. An interesting finding to be noted is that the different drugs have particular effects in distinct subtypes of soft-tissue sarcoma; however, it has to be taken into account that the number of patients included in those phase II trials are limited. The role of the newer agents (e.g. patupilone derivates, brostallicin) is currently not definable. The so-called selective therapy targeting vascular endothelial growth factor (receptor), epidermal growth factor receptor, c-kit, Raf kinase or platelet-derived growth factor receptor and bcl-2 antisensing, proteasome, protein kinase C/B, and mammalian target of rabamycin inhibition will continue to be tested in gastrointestinal stromal tumors patients refractory to imatinib mesylate as well as in selected sarcoma subtypes.

show abstract

“…Brostallicin has been tested in a phase II study carried out by the EORTC Soft Tissue and Bone Sarcoma Group [73]. Forty-two patients were treated in this study, and two partial responses plus 17 stable diseases were reported.…”

Section: Brostallicinmentioning

confidence: 99%